Welcome to our dedicated page for Dyadic International news (Ticker: DYAI), a resource for investors and traders seeking the latest updates and insights on Dyadic International stock.
Dyadic International, Inc. (OTCQX: DYAI) is a global biotechnology company renowned for its pioneering work in gene expression systems. The company has developed the C1 Expression System, a patented and proprietary technology utilizing the Thermothelomyces heterothallica fungus, which has set new standards in the production of commercial quantities of industrial enzymes and other proteins. This innovative platform is licensed to industry giants like Abengoa Bioenergy, BASF, and Codexis for various non-pharmaceutical applications.
Core Business
Dyadic's core business revolves around the advancement and application of the C1 Expression System. This platform is instrumental in producing biologic vaccines and drugs at a faster rate, in larger volumes, and at a lower cost, thereby making healthcare more accessible and affordable. By enhancing protein production capabilities, Dyadic aims to meet the growing demands of drug developers and manufacturers, ultimately improving patient care and saving lives.
Recent Achievements and Current Projects
Dyadic has made significant strides in the biotechnology sector. The company has successfully showcased the efficiency of the C1 Expression System in various industrial applications. Currently, Dyadic is focusing on expanding its influence in the pharmaceutical sector, aiming to leverage C1's potential for large-scale production of human and animal vaccines and therapeutics.
Financial Condition
With a solid financial foundation, Dyadic continues to invest in research and development, ensuring the continuous improvement of its gene expression technology. The company's partnerships and licensing agreements with major industry players underscore its financial stability and growth potential.
Partnerships and Collaborations
Dyadic's collaborative efforts with companies like Abengoa Bioenergy, BASF, and Codexis highlight its pivotal role in the biotechnology landscape. These partnerships enable Dyadic to expand the application of the C1 Expression System beyond pharmaceuticals, touching sectors such as food, nutrition, and wellness.
Products and Services
Dyadic's primary product, the C1 Expression System, is a game-changer in gene expression and protein production. The company is dedicated to advancing this technology to meet the evolving needs of the biopharmaceutical industry, ensuring more efficient and cost-effective production processes.
Contact Information
For further information, inquiries can be directed to Ping W. Rawson, Chief Financial Officer, at (561) 743-8333 or via email at ir@dyadic.com.
Dyadic International (NASDAQ: DYAI), a biotechnology company, announced participation in two key industry events this July 2022.
The Bio-Manufacturing Innovation Summit will be held on July 7-8 at Rutgers University, with a presentation by Mark Emalfarb. The NIIMBL 2022 National Meeting is scheduled for July 26-28 in Washington DC, featuring a poster session by Emalfarb.
Dyadic's management will be available for one-on-one meetings during these events. For more details, visit Dyadic's website.
Dyadic International, Inc. (NASDAQ: DYAI) announced its participation in three industry events in June 2022, aimed at advancing its proprietary C1 protein production platform. The events are:
- Vaccine Technology VIII: June 12-17, 2022, Sitges, Spain
- BIO International Convention: June 13-16, 2022, San Diego, CA
- Future Food-Tech Alternative Proteins: June 21-22, 2022, New York, NY
Management will be available for one-on-one meetings. The C1 platform is focused on reducing costs and enhancing the efficacy of biologic vaccines and drugs.
Dyadic International (NASDAQ: DYAI) announced that CEO Mark Emalfarb will present at the 2022 Jefferies Healthcare Conference on June 9, 2022, at 3:00 PM ET. The presentation will showcase Dyadic's proprietary C1-cell protein production platform aimed at enhancing biologic vaccines and drugs. A live webcast will be available for viewing, and a replay will be archived on the company's website. Investors can also arrange one-on-one meetings with the CEO for more detailed discussions.
Dyadic International (NASDAQ: DYAI) announced its participation in the 2022 H.C. Wainwright Global Investment Conference held from May 23-26, 2022, at the Fontainebleau Miami Beach Hotel. President and CEO, Mark Emalfarb, will present on May 25, 2022, at 12:30 PM ET. The management team will also host one-on-one meetings, accessible through a request at hzosiak@dyadic.com. Dyadic focuses on developing its proprietary C1-cell protein production platform to enhance the efficiency and cost-effectiveness of biologic vaccines and drugs.
Dyadic International (NASDAQ: DYAI) reported a 40.8% revenue increase in Q1 2022, reaching approximately $534,000. The company secured a new collaboration with a global food ingredients firm and a license deal with Phibro for animal vaccines. Positive developments include advancing a first-in-human clinical trial application for the DYAI-100 COVID-19 vaccine in South Africa, while a C1-produced antibody showed efficacy against Omicron variants. Cash and investments stood at $17.5 million as of March 31, 2022, against a net loss of approximately $2.49 million.
Dyadic International, Inc. (NASDAQ: DYAI) has entered into a Joint Development Agreement with a Global Food Ingredients Company to produce animal-free ingredient products. The project is fully funded with €3.6 million. Dyadic will develop proprietary production cell lines and can earn success and commercialization fees, along with royalties on sales. This partnership illustrates Dyadic's capacity to leverage its C1 protein production platform beyond biopharmaceuticals, tapping into emerging markets and enhancing its value in biomanufacturing.
Dyadic International announced positive results from a toxicology study of its COVID-19 vaccine candidate, DYAI-100, published in Toxicologic Pathology. The study revealed an excellent safety profile and strong immunogenic responses in animal models. The findings support Dyadic’s upcoming First-In-Human clinical trial and validate its C1-cell protein production platform, which aims to lower biopharmaceutical production costs. This marks Dyadic's third peer-reviewed publication in 2022 regarding the efficacy and safety of its products.
Dyadic International, Inc. (NASDAQ: DYAI) announced its upcoming financial results report for Q1 2022, scheduled for May 12, 2022, at 5:00 p.m. ET. The company specializes in using its proprietary C1-cell protein production platform to enhance the development and production of biologic drugs and vaccines at lower costs. The conference call will discuss financial performance and future strategies, accessible via specific dial-in numbers or a webcast link. Dyadic aims to leverage its C1 technology to improve access to biologics and save lives.
Dyadic International, Inc. (NASDAQ: DYAI) announced that its licensee, Epygen Biotech, received funding from India's Department of Biotechnology to support Phase 1 and 2 clinical trials of a COVID-19 vaccine using Dyadic's C1 protein production platform. Epygen aims to develop a low-cost vaccine, anticipated to be priced around $2 per dose, targeting the production of 100 million doses annually. Additionally, Epygen plans to raise $26 million for Phase 3 trials to enhance production capacity and expedite vaccine availability.
Dyadic International, Inc. (NASDAQ: DYAI), a global biotechnology company, announced its participation in key scientific meetings in April 2022. The company will present its proprietary C1-cell protein production platform aimed at enhancing biologic vaccine and drug development during the Microbial Engineering II conference in Portugal and the World Vaccine Congress in Washington, DC. Presentations will cover topics including therapeutic protein production and innovative vaccine manufacturing solutions, showcasing how C1 can reduce costs and improve efficiency in biopharmaceuticals.
FAQ
What is the current stock price of Dyadic International (DYAI)?
What is the market cap of Dyadic International (DYAI)?
What does Dyadic International, Inc. do?
What is the C1 Expression System?
Who are Dyadic's partners?
What sectors does Dyadic serve?
How does Dyadic's C1 Expression System benefit the healthcare sector?
Where is Dyadic International, Inc. headquartered?
What recent projects is Dyadic working on?
How can I contact Dyadic for more information?
What is Dyadic's stock symbol?
What is the main goal of Dyadic International, Inc.?
